Abstract
Cancer-associated fibroblasts (CAFs) are senescent fibroblasts in tumor nest, which trigger a signaling center to remodel a desmoplastic tumor niche. CAF’s functions in cancer are closely similar to myofibroblasts during the wound healing process. They can produce cytokines, enzymes, and protein- or RNA-containing exosomes to alter the function of surrounding cells. Non-- coding RNAs, including microRNAs and long non-coding RNAs, modulate pathologic mechanisms in cancer. Dysregulation of these RNAs influences the formation and function of CAFs. Furthermore, it has been demonstrated that CAFs, by releasing non-coding RNAs-containing exosomes, affect the tumor cells’ behavior. CAFs also secrete mediators such as chemokines to alter the expression of non-coding RNAs in the tumor microenvironment. This study aimed to discuss the role of non-coding RNAs in CAF development in cancer. Additionally, we have shed light on the therapeutic approaches to develop the strategies based on the alteration of non-coding RNAs in cancer.
Keywords: Non-coding RNA, miRNA, lncRNA, cancer, cancer-associated fibroblasts, fibroblasts.
Current Drug Targets
Title:The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy
Volume: 22 Issue: 13
Author(s): Arezoo G. Shabgah, Hamed Mohammadi, Pouya Goleij, Mahdiyeh Hedayati-Moghadam, Arash Salmaninejad and Jamshid G. Navashenaq*
Affiliation:
- Noncommunicable Diseases Research Center, Bam University of Medical Sciences, Bam,Iran
Keywords: Non-coding RNA, miRNA, lncRNA, cancer, cancer-associated fibroblasts, fibroblasts.
Abstract: Cancer-associated fibroblasts (CAFs) are senescent fibroblasts in tumor nest, which trigger a signaling center to remodel a desmoplastic tumor niche. CAF’s functions in cancer are closely similar to myofibroblasts during the wound healing process. They can produce cytokines, enzymes, and protein- or RNA-containing exosomes to alter the function of surrounding cells. Non-- coding RNAs, including microRNAs and long non-coding RNAs, modulate pathologic mechanisms in cancer. Dysregulation of these RNAs influences the formation and function of CAFs. Furthermore, it has been demonstrated that CAFs, by releasing non-coding RNAs-containing exosomes, affect the tumor cells’ behavior. CAFs also secrete mediators such as chemokines to alter the expression of non-coding RNAs in the tumor microenvironment. This study aimed to discuss the role of non-coding RNAs in CAF development in cancer. Additionally, we have shed light on the therapeutic approaches to develop the strategies based on the alteration of non-coding RNAs in cancer.
Export Options
About this article
Cite this article as:
Shabgah G. Arezoo , Mohammadi Hamed , Goleij Pouya , Hedayati-Moghadam Mahdiyeh , Salmaninejad Arash and Navashenaq G. Jamshid *, The Role of Non-coding Genome in Cancer-associated Fibroblasts; Stateof- the-Art and Perspectives in Cancer Targeted Therapy, Current Drug Targets 2021; 22 (13) . https://dx.doi.org/10.2174/1389450122666210216091953
DOI https://dx.doi.org/10.2174/1389450122666210216091953 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Epigenetic Remodeling of Chromatin Architecture: Exploring Tumor Differentiation Therapies in Mesenchymal Stem Cells and Sarcomas
Current Stem Cell Research & Therapy Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism Counselling and Cognitive Behaviour Interventions Delivered to Reduce Psychological Morbidity and Improve Quality of Life in Gynaecological Cancer Patients: Recent Achievements
Current Women`s Health Reviews Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets The Role of Blood-Brain Barrier Transporters in Pathophysiology and Pharmacotherapy of Stroke
Current Pharmaceutical Design An Agathokakological Tale of Δ<sup>9</sup>-THC: Exploration of Possible Biological Targets
Current Drug Targets Construction and Comprehensive Analysis of a Special Competitive Endogenous RNAs Network to Reveal Potential Prognostic Biomarkers for Endometrial Carcinoma
Current Bioinformatics Angiogenesis and Microvasculature in the Female Reproductive Organs: Physiological and Pathological Implications
Current Pharmaceutical Design Cellular Communication in Bone Homeostasis and the Related Anti-osteoporotic Drug Development
Current Medicinal Chemistry Efficacy and Safety of the Combination of Docetaxel (Taxotere®) with Targeted Therapies in the Treatment of Solid Malignancies
Current Drug Targets Endothelial Cell Senescence and Inflammaging: MicroRNAs as Biomarkers and Innovative Therapeutic Tools
Current Drug Targets Structural and Functional Characterization of the Proteins Responsible for N<sup>6</sup>-Methyladenosine Modification and Recognition
Current Protein & Peptide Science Achievements and Challenges of Proteomics in the Study of Rheumatoid Arthritis
Current Topics in Medicinal Chemistry Gender Disparity in Pediatric Diseases
Current Molecular Medicine BRCA1 as Target for Breast Cancer Prevention and Therapy
Anti-Cancer Agents in Medicinal Chemistry Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry